Innovations in Cell and Gene Therapy at Upcoming Conference

Bio-Techne Corporation's Upcoming Show at a Major Conference

Bio-Techne Corporation (NASDAQ: TECH) is set to make a significant impact at the upcoming Advanced Therapies Week. This event presents an excellent opportunity for the company to showcase its innovative ProPak™ GMP cytokines alongside a comprehensive portfolio of solutions aimed at enhancing the development and manufacturing of cell and gene therapies.

Showcasing Advanced Therapeutic Solutions

During this major event, attendees can visit Bio-Techne's booth 517. The display will highlight the company's robust offerings in cell and gene therapy workflow solutions, focusing on reproducibility and scalability. Among the advanced products on exhibit are the newly launched ProPak liquid GMP cytokines, designed to integrate with Wilson Wolf's G-Rex bioreactor systems, facilitating a closed process that optimizes cytokine delivery for T cell manufacturing.

Innovative Product Demonstrations

Attendees will also have the chance to see product demonstrations, including the Ella™ automated ELISA platform and Simple Plex™ assays. These technologies provide efficient solutions for quality control release testing, emphasizing Bio-Techne's commitment to precision and excellence in the realm of protein analytical instruments.

Key Presentations and Discussions

Dr. David Hermanson, Principal Scientist for Cell & Gene Therapy Research & Development at Bio-Techne, will be leading a breakout session focused on the topic of closed system manufacturing. He aims to address the best practices and strategies that can be employed to ensure flexibility and scalability throughout the stages of cell therapy programs. His presentation will encompass crucial regulatory, economic, and quality control considerations essential for selecting the right manufacturing platforms.

Upcoming Breakout Session

This highly anticipated session, titled "Closed Systems, Open Possibilities: Considerations for Futureproofing Cell Therapy Manufacturing," will take place on January 21 at 12:15 PM in Theatre 1. Dr. Hermanson's insights are expected to provide valuable knowledge to industry professionals.

Interactive Innovation Zone

In addition to informative breakout sessions, Bio-Techne will also organize a product demonstration in the Innovation Zone on January 22 at 10:00 AM. This demonstration will focus on how ProPak cytokines can streamline T cell manufacturing workflows using G-Rex bioreactors, showcasing the advantages of closed system solutions.

Company Commitment and Vision

Will Geist, President of Bio-Techne's Protein Sciences Segment, expressed the company's dedication to developing efficient manufacturing solutions for transformative cell and gene-modified cell therapies. He stated, "ProPak GMP Cytokines allow for highly simplified closed-system expansion of CAR-T and TCR-T cell products with significant enhancement in cell characteristics. We are eager to showcase our extensive range of cell and gene therapy workflow solutions during this vital conference."

About Bio-Techne

Bio-Techne Corporation is a leading global life sciences company that offers innovative tools and bioactive reagents aimed at both research and clinical diagnostic sectors. Their extensive product portfolio supports crucial scientific investigations, drug discovery efforts, and precise clinical testing and diagnostics. Last fiscal year, Bio-Techne achieved approximately $1.2 billion in net sales, underscoring its pivotal role in the life sciences landscape with around 3,100 employees globally.

About ScaleReady

ScaleReady, a key partner of Bio-Techne, specializes in the field of cell and gene-modified cell therapy through its G-Rex centered manufacturing platform. Their platform is pivotal for organizations focusing on the scalable and cost-effective production of CGT drug products. Currently, over 800 organizations leverage the capabilities of ScaleReady, with its technology used in around 50% of CGT clinical trials and five commercially approved CGT drugs. Users of ScaleReady benefit from significantly reduced development times and costs on their journey toward commercializing CGT products.

Frequently Asked Questions

1. What is the role of Bio-Techne at the upcoming conference?

Bio-Techne will showcase its innovations in GMP cytokines and cell and gene therapy solutions, enhancing manufacturing processes.

2. Who will present at the event?

Dr. David Hermanson will present key insights on closed system manufacturing and its importance in therapy development.

3. When will the product demonstration take place?

The product demonstration by Bio-Techne will occur on January 22 at 10:00 AM in the Innovation Zone.

4. What are ProPak GMP Cytokines used for?

ProPak GMP Cytokines are utilized for the streamlined expansion of CAR-T and TCR-T cell products in closed systems.

5. How can ScaleReady's technology impact CGT development?

ScaleReady's G-Rex platform accelerates the development of CGT products by providing a flexible, scalable manufacturing approach.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.